Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
12/16/18
12/16
04:55
12/16/18
04:55

European Society for Medical Oncology (ESMO) to hold a conference

ESMO Immuno-Oncology Congress 2018 will be held in Geneva, Switzerland on December 13-16.

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

RHHBY

Roche

$0.00

(0.00%)

CELG

Celgene

$68.20

-1.55 (-2.22%)

MRK

Merck

$76.50

-1.94 (-2.47%)

PFE

Pfizer

$43.84

-0.71 (-1.59%)

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

NEO

NeoGenomics

$13.25

-0.18 (-1.34%)

SGEN

Seattle Genetics

$60.46

-0.5 (-0.82%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

IMV

IMV Inc

$5.65

-0.14 (-2.42%)

  • 18

    Dec

  • 24

    Dec

  • 29

    Dec

  • 11

    Jan

  • 11

    Jan

  • 24

    Jan

  • 16

    Feb

  • 18

    Mar

  • 20

    May

BMY Bristol-Myers
$52.11

-1.54 (-2.87%)

12/06/18
BMOC
12/06/18
UPGRADE
Target $60
BMOC
Outperform
Bristol-Myers upgraded to Outperform at BMO Capital on better Opdivo sales
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Bristol-Myers to Outperform from Market Perform and raised his price target to $60 from $56, saying the risk-reward on the stock at current price "seems attractive". The analyst notes that a number of R&D setbacks have reduced expectations for the company's immuno-oncology franchise, raising his forecasts on Opdivo to reflect the "low" street consensus. Arfaei adds that the Street is modeling flattish gross margins, but his forecast calls for a 2% improvement by 2021 with Opdivo revenue expectations coming about 10%-15% above consensus. The analyst also raises his FY19 EPS view to $4.18 from $3.93 to reflect the more optimistic Opdivo targets.
12/06/18
JPMS
12/06/18
NO CHANGE
Target $70
JPMS
Overweight
JPMorgan still sees path to substantial Opdivo growth despite Bristol's setbacks
JPMorgan analyst Chris Schott said that investors are clearly concerned about Opdivo growth following several recent setbacks for Bristol-Myers, including mixed TMB data, pending RCC competition, and a failed SCLC study, but he still sees a path to substantial growth for the drug based on the numerous important readouts in both lung and non-lung indications coming in the next 12 months. Meanwhile, his analysis suggests Bristol-Myers' share price reflects little, if any, Opdivo growth from current levels. Given his view, and its convergence with what he believes to be the consensus view, on Opdivo, Schott sees the long term risk/reward for Bristol shares as highly attractive and keeps an Overweight rating on the stock with a $70 price target.
12/06/18
12/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Activision Blizzard (ATVI) upgraded to Overweight from Neutral at JPMorgan with analyst Alexia Quadrani saying the stock is down 45% from an all-time high in early October, and now trades at 16.5 times forward consensus earnings, compared to 25.5 times and 23.0 times on average over the prior one and three year periods. 2. Bristol-Myers (BMY) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei saying the risk-reward on the stock at current price "seems attractive." 3. Hostess Brands (TWNK) upgraded to Overweight from Neutral at JPMorgan analyst Ken Goldman saying by this time next year, today's two major headwinds - lost business with Walmart (WMT) and the "EBITDA-hemorrhaging" Cloverhill acquisition - will be lapped and potentially become tailwinds. 4. Spirit Airlines (SAVE) upgraded to Outperform from Neutral at with analyst Jose Caiado De Sousa saying after a "massive" Q4 unit revenue guidance boost last week, the analyst sees further upside in the equity into H1 of 2019, with expected continued momentum in non-ticket revenue production amid a lower oil environment and a benign competitive backdrop. 5. Synopsys (SNPS) upgraded to Buy from Hold at Benchmark with analyst Gary Mobley citing slightly better than expected Q4 results and in-line FY19 guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
RHHBY Roche
$0.00

(0.00%)

12/11/18
SBSH
12/11/18
NO CHANGE
SBSH
Neutral
Citi closes positive catalyst watch on Roche
Citi analyst Andrew Baum closed his positive catalyst watch on Roche following the company's "impressive" CD20-TCB data. The analyst keeps a Neutral rating on the shares.
12/11/18
JEFF
12/11/18
INITIATION
JEFF
Buy
Roche assumed with a Buy at Jefferies
Jefferies analyst Peter Welford assumed coverage of Roche with a Buy rating and CHF 300 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum." He calls Roche his most preferred EU large-cap Pharma name.
12/11/18
12/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at DZ Bank. 2. Coherent (COHR) initiated with a Neutral at Goldman Sachs. 3. SMTC Corp. (SMTX) initiated with a Buy at B. Riley FBR. 4. Denny's (DENN) initiated with a Buy at Maxim. 5. Roche (RHHBY) assumed with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CELG Celgene
$68.20

-1.55 (-2.22%)

12/03/18
PIPR
12/03/18
NO CHANGE
PIPR
Overweight
Regeneron's REGN1979 'best in show' thus far at ASH, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond calls Regeneron Pharmaceuticals' (REGN) REGN1979 the "best in show" thus far at this year's American Society of Hematology meeting. The analyst says this weekend's updates were largely consistent with his expectations except for the "overwhelmingly impressive data" from REGN1979 in relapsed or refractory follicular lymphoma. This asset could serve as a "significant value driver" for Regeneron shares and the stock is likely to be up sharply today, Raymond tells investors in a research note. He adds that REGN1979 is currently not in his Regeneron model. Following the weekend's updates the analyst keeps Overweight ratings on BioMarin (BMRN) and Regeneron and a Neutral rating on Celgene (CELG).
11/28/18
GSCO
11/28/18
NO CHANGE
Target $284
GSCO
Buy
Goldman Sachs sees Bluebird Bio as 'compelling' buy for ASH, 2019
Goldman Sachs analyst Salveen Richter notes that at the American Society of Hematology meeting, Bluebird Bio (BLUE) will present data across its pipeline, with the key focus on Bluebird Bio/Celgene's (CELG) lead value driver CAR-T bb2121 in r/r MM which he expects will maintain its first-mover advantage and potentially best-in-class status in the context of BCMA competitors. Additionally, Richter notes that Bluebird Bio's recent pull back has created an attractive entry point to buy ahead of ASH and into a compelling de-risked genomic medicine company positioned to capitalize on its multi-modality approach to drug discovery to support the next leg of the story as he looks to the unveiling of new programs in 2019-plus and three likely drug approvals in 2019/2020 with additional launches post. He reiterates a Buy rating and $284 price target on Bluebird Bio shares.
11/26/18
JEFF
11/26/18
NO CHANGE
Target $115
JEFF
Buy
Celgene trades at lowest P/E in Biotech history, says Jefferies
At 6.5 times 2019 estimated earnings, Celgene trades at the lowest price-to-earnings multiple in the history of Biotech, Jefferies analyst Michael Yee tells investors in a research note. The stock has dropped since the Q3 report partially on some worries around the Juno deal but largely on Street sentiment worsening and lack of clarity on what's the catalyst other than it's cheap, which isn't a catalyst in a bear market, Yee tells investors in a research note. The analyst thinks "this changes as precedent suggests," but he admits that the "timing is difficult." Celgene is trading at the analyst's "no-pipeline" value of $65 per share. The stock "could be one to recover on an improved biotech tape," says Yee, who keeps a Buy rating on Celgene with a $115 price target. The stock closed Friday down 89c to $66.65.
11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
MRK Merck
$76.50

-1.94 (-2.47%)

10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
10/31/18
SBSH
10/31/18
NO CHANGE
Target $84
SBSH
Buy
Merck price target raised to $84 from $79 at Citi
Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck's market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.
PFE Pfizer
$43.84

-0.71 (-1.59%)

11/19/18
CANT
11/19/18
NO CHANGE
Target $53
CANT
Overweight
Pfizer's oncology assets are underappreciated, says Cantor Fitzgerald
Pfizer's oncology assets will make up 13% of its total 2018 sales and they will accelerate the company's sales growth for the foreseeable future, but these drugs are underappreciated, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Pfizer has said that through 2022 it expects 15 potential blockbusters to be launched, and oncology drugs are represented in these opportunities, the analyst points out. She sees upside to consensus estimates and keeps an Overweight rating on Pfizer with a $53 price target.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
12/11/18
JPMS
12/11/18
DOWNGRADE
Target $46
JPMS
Neutral
Pfizer downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Christopher Schott downgraded Pfizer to Neutral with an unchanged price target of $46. The shares closed yesterday up 48c to $44.40. The analyst cites valuation for his move to the sidelines after a "strong" 2018 which has to the stock up over 20% year-to-date. Further, he believes Pfizer's product pipeline needs to expand following the patent expiration of Lyrica in 2019.
12/11/18
12/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Overweight at JPMorgan with analyst Christopher Schott citing valuation. 2. Splunk (SPLK) resumed with a Neutral from Buy at Guggenheim with analyst Imtiaz Koujalgi saying while the company's fundamentals are strong, he's "looking for more clarity." 3. CalAmp (CAMP) downgraded to Outperform from Strong Buy at First Analysis and to Market Perform from Outperform at Northland. 4. Acorda Therapeutics (ACOR) downgraded to Sell from Neutral at Goldman Sachs with analyst Salveen Richter saying the commercial outlook for Inbrija appears limited. 5. Versum Materials (VSM) downgraded to Sell from Neutral at Goldman Sachs with analyst Toshiya Hari saying while he remains constructive on the Semiconductor Materials sub-sector broadly, he believes the market is underestimating the extent to which weaker semiconductor capital expenditures could negatively impact the Delivery Systems and Services segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FLDM Fluidigm
$7.79

-0.39 (-4.77%)

11/02/18
PIPR
11/02/18
UPGRADE
Target $10
PIPR
Overweight
Fluidigm upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Fluidigm to Overweight and raised his price target for the shares to $10 from $6.70. Mass Cytometry lead the beat in Q3 with both strong instrument placements and consumables growth while management remains confident on long-term adoption trends, Quirk tells investors in a post-earnings research note. The analyst is impressed with Mass Cytometry adoption and upgraded the shares to reflect that.
NEO NeoGenomics
$13.25

-0.18 (-1.34%)

10/23/18
RAJA
10/23/18
INITIATION
Target $16
RAJA
Outperform
NeoGenomics resuming with an Outperform at Raymond James
Raymond James analyst John Hsu resumed coverage on NeoGenomics with an Outperform and $16 price target telling investors it is well positioned as a leading pure play oncology testing company.
10/24/18
FANA
10/24/18
UPGRADE
Target $18
FANA
Strong Buy
NeoGenomics upgraded to Strong Buy from Outperform at First Analysis
First Analysis analyst Joseph Munda upgraded NeoGenomics to Strong Buy and raised his price target for the shares to $18 from $16. The analyst views the company's acquisition of clinical oncology testing leader Genoptix as a "major positive." The combined company should benefit from greater geographical coverage, a broader test menu, enhanced service capabilities, and deeper access to oncologists, Munda tells investors in a research note.
10/31/18
CHLM
10/31/18
NO CHANGE
Target $22
CHLM
Buy
NeoGenomics price target raised to $22 from $17 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for NeoGenomics to $22 from $17 given "excellent" Q3 results and as Genoptix acquisition adds another layer of growth. The analyst reiterates a Buy rating on the shares.
11/01/18
BNCH
11/01/18
NO CHANGE
Target $22
BNCH
Buy
NeoGenomics price target raised to $22 from $16 at Benchmark
Benchmark analyst Bruce Jackson noted that NeoGenomics reported earnings and revenue that beat his estimates and the company raised its revenue and adjusted EPS expectations. After raising both his estimates for 2018 and 2019 and raising the multiple he applies, Jackson lifted his price target on NeoGenomics shares to $22 and keeps a Buy rating on the stock.
SGEN Seattle Genetics
$60.46

-0.5 (-0.82%)

12/04/18
WBLR
12/04/18
NO CHANGE
WBLR
Outperform
Seattle Genetics' T-cell lymphoma data best case scenario, says William Blair
The "quality and robustness" of the data Seattle Genetics reported from the successful Phase III Ecehlon-2 study, which assesses the safety and efficacy of Adcetris plus a three-drug chemotherapy regimen versus the standard of care four-drug chemotherapy regimen in frontline mature T-cell lymphomas, represent the "best case scenario," William Blair analyst Andy Hsieh tells investors in a research note. The analyst highlights that the indication was approved 11 days after Seattle Genetics submitted the regulatory application to the FDA, which took advantage of the Real-Time Oncology Review Program. He believes Adcetris will be "quickly adopted" in the frontline mature T-cell lymphoma setting, a $400M market in the United States alone. The analyst keeps an Outperform rating on the shares.
11/27/18
PIPR
11/27/18
NO CHANGE
Target $66
PIPR
Neutral
Piper gets positive feedback on Seattle Genetics label expansion
Piper Jaffray analyst Joseph Catanzaro conducted two key opinion leader calls to gauge sentiment around the data included in Seattle Genetics' Echelon-2 label expansion of Adcetris into CD30+ front-line T-cell lymphoma. The leaders provided "overwhelmingly positive feedback" specifically for anaplastic large cell lymphoma patients, and dismissed any concerns cited with Echelon-1, Catanzaro tells investors in a research note. The analyst, however, awaits greater clarity on the non-ALCL subgroup analyses at the upcoming American Society of Hematology meeting and reiterates a Neutral rating on Seattle Genetics with a $66 price target.
11/16/18
COWN
11/16/18
NO CHANGE
Target $71
COWN
Market Perform
Seattle Genetics risk/reward favorable ahead of ASH, says Cowen
Cowen analyst Boris Peaker said the risk/reward for Seattle Genetics ahead of the ASH meeting is favorable given the shares' recent selloff. The company announced that ECHELON-2 met its primary endpoint and demonstrated improvement in CR and OS for A+CHP over standard of care CHOP, noted Peaker, who maintained his Market Perform rating and $71 price target on Seattle Genetics shares.
10/26/18
BOFA
10/26/18
DOWNGRADE
Target $55
BOFA
Underperform
Seattle Genetics cut to Underperform at BofA/Merrill on slower Adcetris ramp
As reported earlier, BofA/Merrill analyst Tazeen Ahmad downgraded Seattle Genetics to Underperform from Neutral and lowered his price target to $55 from $72 after its Q3 update on Adcetris yesterday. The analyst notes that the key driver in the rating change is the reset of expectations for the Adcetris ramp, adding that a poll of physicians also indicates that the "current low cost standard of care" in Hodgkin's will remain their first choice among the earlier stage 1-2 patients.
TKPYY Takeda Pharmaceutical
$0.00

(0.00%)

09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
11/06/18
RHCO
11/06/18
NO CHANGE
Target $190
RHCO
Buy
Shire price target lowered to $190 from $205 at SunTrust
SunTrust analyst John Boris lowered his price target on Shire (SHPG) to $190 to reflect the impact of the USD appreciation against GBP while also lowering his FY18 EPS view to $15.11 from $15.18. The analyst notes that the investment focus for Shire falls on the November 20th vote by E.U. regulators on its merger with Takeda (TKPYY), adding that the company is on track to secure that approval and for shareholders to vote on the deal in January of next year.
12/12/18
RHCO
12/12/18
DOWNGRADE
Target $175
RHCO
Hold
Shire downgraded to Hold at SunTrust on Takeda merger
As reported earlier, SunTrust analyst John Boris downgraded Shire (SHPG) to Hold from Buy and lowered his price target to $175 from $190. The analyst cites the changes in FX rates and Takeda (TKPYY) share price in shifting his price target, but expects the deal to close under the same terms on January 8th with no "meaningful hurdles" left to clear until then.
IMV IMV Inc
$5.65

-0.14 (-2.42%)

TODAY'S FREE FLY STORIES

AAWW

Atlas Air

$49.61

-0.5 (-1.00%)

08:22
01/24/19
01/24
08:22
01/24/19
08:22
Conference/Events
The Wings Club to hold a luncheon meeting »

President & CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

CP

Canadian Pacific

$195.71

0.02 (0.01%)

08:21
01/24/19
01/24
08:21
01/24/19
08:21
Recommendations
Canadian Pacific analyst commentary  »

Canadian Pacific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

08:21
01/24/19
01/24
08:21
01/24/19
08:21
Conference/Events
European Central Bank President Draghi to hold press conference »

ECB President Draghi…

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:20
01/24/19
01/24
08:20
01/24/19
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
01/24/19
01/24
08:20
01/24/19
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
01/24/19
01/24
08:20
01/24/19
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$174.98

-1.01 (-0.57%)

08:20
01/24/19
01/24
08:20
01/24/19
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$64.45

0.22 (0.34%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$61.79

-0.6 (-0.96%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$105.40

0.16 (0.15%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$52.42

-0.34 (-0.64%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

08:18
01/24/19
01/24
08:18
01/24/19
08:18
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XLU

Utilities SPDR

$53.79

0.56 (1.05%)

08:18
01/24/19
01/24
08:18
01/24/19
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$52.57

0.58 (1.12%)

08:18
01/24/19
01/24
08:18
01/24/19
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$89.55

0.07 (0.08%)

08:18
01/24/19
01/24
08:18
01/24/19
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$144.61

-0.36 (-0.25%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$245.75

1.64 (0.67%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$133.76

0.82 (0.62%)

, UNH

UnitedHealth

$267.12

1.44 (0.54%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Recommendations
HCA Healthcare, UnitedHealth, Johnson & Johnson analyst commentary  »

HCA Healthcare elevated…

HCA

HCA Healthcare

$133.76

0.82 (0.62%)

UNH

UnitedHealth

$267.12

1.44 (0.54%)

JNJ

Johnson & Johnson

$128.82

0.06 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 29

    Jan

  • 18

    Feb

  • 19

    Feb

  • 28

    May

SPY

SPDR S&P 500 ETF Trust

$263.42

0.37 (0.14%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$25.72

0.01 (0.04%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

SMH

Market Vectors Semiconductor

$89.82

-0.36 (-0.40%)

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

Invesco QQQ Trust

$162.20

0.04 (0.02%)

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Technical Analysis
Invesco QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

$0.00

(0.00%)

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Conference/Events
JPMorgan to hold a conference »

Thailand Conference will…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.